Editorially reviewed · Last updated September 8, 2026 · How we review
Part of YouTube & Expert Fact Checks.
JD Denham on Retatrutide: Triple Agonist Mechanism, Dosing, and Fat Loss Claims — Fact Check
This page fact-checks their key claims against published clinical trial data from the Phase 2 NEJM paper and Eli Lilly's TRIUMPH Phase 3 program.
This review checks the claims recorded in our existing article against primary research. We could not retrieve an independent transcript for this update, so the quoted wording and timestamps have not been freshly verified.
The Triple Agonist Mechanism
Haas explains that retatrutide works on three receptors — GLP-1 for appetite suppression, GIP for nutrient partitioning and insulin sensitivity, and glucagon (GCG) for boosting metabolic rate and burning fat. He contrasts this with semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP).
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide is a triple agonist: GLP-1, GIP, and glucagon | Confirmed. Jastreboff et al. (2023) NEJM: retatrutide is a single peptide with agonism at GLP-1, GIP, and glucagon receptors. Receptor activity measured in laboratory assays does not quantify clinical benefit. | Accurate |
| Semaglutide only works on GLP-1 | Correct. Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide targets GLP-1 and GIP (dual agonist). | Accurate |
| GLP-1 makes your stomach digest things slowly — that's the appetite suppression | Gastric emptying delay is a well-established GLP-1 effect. The NEJM Phase 2 paper describes appetite suppression as a primary GLP-1 mechanism. | Accurate |
| GIP acts as a nutrient partitioner — puts protein into muscle | Preclinical GIP research includes effects on adipose tissue. However, no published human trial demonstrates GIP specifically "partitioning protein to muscles." This is speculative. | Overstated |
| The glucagon component boosts metabolic rate and tells fat cells to burn off | Glucagon receptor agonism increases hepatic fat oxidation and energy expenditure in preclinical models. However, a cotadutide Phase 2a trial found that in humans, weight loss was "predominantly via reduced energy intake rather than changes in energy expenditure." Directionally correct but magnitude uncertain. | Approximately accurate |
The basic framework is correct — retatrutide genuinely is a triple agonist, and each receptor does play a distinct role. The oversimplification is in attributing muscle-sparing specifically to GIP "nutrient partitioning," which is not supported by published human data.
Muscle Loss: Semaglutide vs Retatrutide
Haas claims that people on semaglutide "lost fat and muscle equally" and that retatrutide protects muscle because GIP partitions protein into muscles.
| Claim | Published Data | Verdict |
|---|---|---|
| People on semaglutide lost fat and muscle equally | The STEP 1 DXA analysis distinguishes fat mass from lean mass. Lean mass is not synonymous with skeletal muscle, so the claim that fat and muscle were lost equally is not established. | Significantly wrong |
| Retatrutide protects muscle because GIP partitions protein to muscles | The retatrutide DXA substudy was conducted in adults with type 2 diabetes over 36 weeks; it is not a direct comparison with semaglutide. No published trial has demonstrated that GIP specifically partitions protein to muscles. | Overstated |
| Tirzepatide also helps with muscle preservation compared to semaglutide | The SURMOUNT-1 DXA substudy reported approximately 75% fat mass and 25% lean mass as proportions of weight lost. It did not compare body composition directly with semaglutide. | Not established by this study |
Neither a proven muscle-preservation advantage for retatrutide nor the proposed GIP protein-partitioning explanation is established by these trials. Comparing lean-mass percentages across different populations cannot resolve that question.
The "No Nausea" Claim
Haas claims that retatrutide's higher GIP activity "kills all of the nausea" and that "there is no nausea" on retatrutide, unlike semaglutide or tirzepatide.
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide has no nausea | Phase 2 NEJM data (Jastreboff et al., 2023): the 12 mg group had 45% nausea (28 of 62 participants). Vomiting occurred in 19% of the 12 mg group. | Significantly wrong |
| GIP component kills nausea from GLP-1 | A 2025 Science Advances paper from Eli Lilly showed GIP co-treatment "completely prevented emesis caused by semaglutide" in musk shrews. Clinical translation to humans is plausible but nausea rates in retatrutide trials remain substantial. | Approximately accurate (preclinically) |
| Tirzepatide had some nausea but retatrutide eliminates it | SURMOUNT-1: tirzepatide nausea 24-31% across doses. Retatrutide Phase 2: 45% in the 12 mg group. This disproves the no-nausea claim, but separate trials do not establish comparative tolerability. | Significantly wrong |
This is the most dangerously wrong claim in the episode. Nearly half of participants on the highest retatrutide dose experienced nausea in the Phase 2 trial. GI side effects were described as "transient, mostly mild-to-moderate" and occurred "primarily during dose escalation," but calling them nonexistent is false and could leave new users unprepared.
Brain Function and Mental Clarity
Haas describes experiencing enhanced focus and mental clarity on retatrutide. He attributes this to the glucagon component creating just the right amount of blood sugar through gluconeogenesis, keeping the brain fueled even when fasting.
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide enhances brain function and focus | No published retatrutide trial has measured cognitive endpoints. The Phase 2 and Phase 3 trials did not include neurological or cognitive assessments. | No evidence (anecdotal) |
| The glucagon component creates "just the right amount" of blood sugar for the brain | Glucagon does stimulate hepatic gluconeogenesis. Retatrutide improved glycemic control in Phase 2 (HbA1c reductions of 0.4-0.7% in non-diabetic participants). However, linking this to subjective "brain function" enhancement is speculative. | Overstated |
| GLP-1 receptor agonists have neuroprotective properties | There is a growing body of preclinical research on GLP-1R agonist neuroprotection (reduced neuroinflammation, improved brain insulin signaling). However, direct neuroimaging studies for retatrutide are lacking. | Plausible but unproven for retatrutide |
Haas's personal experience of improved focus is a common anecdotal report among GLP-1 drug users, and there are plausible biological mechanisms. But no clinical trial has measured cognitive outcomes for retatrutide, and attributing this to a specific gluconeogenesis mechanism is speculative.
Retatrutide Dosing Schedule: What They Recommend vs Clinical Trials
Denham shares his personal experience of injecting 1 mg three times per week (Monday, Wednesday, Friday) for a total of 3 mg/week. Haas states the "clinical starting dose is 2 and a half milligrams a week" and recommends titrating up by 0.5 mg per injection.
| Claim | Published Data | Verdict |
|---|---|---|
| Clinical starting dose is 2.5 mg/week | Phase 2 tested several regimens, including 2 mg starts for higher target doses. Phase 3 (TRIUMPH-4): same 2 mg starting dose. There is no 2.5 mg dose in the clinical program. The 2.5 mg figure may be confused with tirzepatide (Mounjaro starts at 2.5 mg). | Misleading |
| Dosing should be split into three injections per week (e.g., 1 mg MWF) | All clinical trials administered retatrutide as a single once-weekly subcutaneous injection. Three-times-weekly dosing has never been studied in any published trial. The half-life supports once-weekly dosing. | Not based on clinical data |
| Weight loss sweet spot is 5-6 mg/week for people who need to lose a lot | Phase 2 tested 1, 4, 8, and 12 mg once weekly. Phase 3 (TRIUMPH-4) tested 9 and 12 mg. The 12 mg group achieved 28.7% weight loss at 68 weeks. There is no published efficacy data for 5-6 mg/week. | Not based on clinical data |
| Titration schedule: increase by 0.5 mg per injection every 2-3 weeks | TRIUMPH-4 started at 2 mg weekly and escalated at four-week intervals through 4 mg and 6 mg to the 9 mg target, with a further step for the 12 mg group. This was a trial protocol, not a licensed dosing schedule. | Not based on clinical data |
The dosing discussion is the most problematic section of the episode. Every dosing recommendation they make — the frequency, the starting dose, the titration schedule, and the target dose — diverges from published clinical trial protocols. Their advice appears to come from gray market peptide community practices rather than the studied regimens that produced the published weight loss and safety data.
Visceral Fat and Metabolic Benefits
Both hosts emphasize that retatrutide is particularly effective at burning visceral (belly) fat, and that this is driven by the glucagon receptor component.
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide burns visceral fat exceptionally well | The published MRI liver substudy reported an 86.0% relative reduction in liver fat at 48 weeks with 12 mg. Liver fat, visceral adipose tissue and total body weight are different measures; this does not substantiate the 42% visceral-fat figure previously cited here. | Approximately accurate |
| The glucagon component specifically targets visceral fat | The human trial does not isolate glucagon’s contribution or establish selective targeting of belly fat. | Unproven mechanism |
| If you are already lean, it will just burn belly fat in a week and a half | Phase 2 trial used a 48-week endpoint. Meaningful body composition changes were measured over months, not days. The claim of visible results in 10 days at a low dose is anecdotal and not supported by trial timelines. | Overstated |
The liver-fat finding is promising, but it does not prove selective belly-fat loss, a visible response within ten days, or superiority to another drug. The substudy enrolled people with at least 10% liver fat at baseline, not already-lean users.
Peptide Stacking Recommendations
The hosts recommend stacking retatrutide with tesamorelin, L-carnitine, 5-amino-1MQ, and MOTS-c for fat burning, and with MK-677 and IGF-1 LR3 for muscle building.
| Claim | Published Data | Verdict |
|---|---|---|
| Tesamorelin targets belly fat and boosts growth hormone | Tesamorelin is FDA-approved for HIV-associated lipodystrophy and reduces visceral fat by stimulating growth hormone. However, it has never been studied in combination with retatrutide. | Partially accurate (but no combination data) |
| L-carnitine tells your body to burn fat over sugar | L-carnitine facilitates fatty acid transport into mitochondria. Systematic reviews show modest fat loss benefits in overweight populations. It does not fundamentally "switch" the body from burning sugar to burning fat. | Overstated |
| MK-677 will offset reta's appetite suppression and help you eat more | MK-677 (ibutamoren) stimulates ghrelin receptors and increases appetite. It is not FDA-approved for any indication and has potential risks including insulin resistance and increased cortisol. | Partially accurate (but safety concerns omitted) |
None of these stacking protocols have been studied in combination with retatrutide. The hosts are describing gray market peptide community practices, not evidence-based protocols. Several of these compounds (MK-677, IGF-1 LR3, 5-amino-1MQ) are research chemicals without FDA approval for any human use.
Frequently Asked Questions
Who are JD Denham and William Hos from Peptide of the Week?
Is retatrutide really a triple agonist?
Does retatrutide really have no nausea?
No. In the Phase 2 obesity trial, 28 of 62 participants in the 12 mg group reported nausea (45%). Most gastrointestinal events were mild or moderate and occurred during escalation. Preclinical GIP anti-emesis findings do not establish the absence of nausea in people.
What is the correct retatrutide dosing schedule?
There is no approved prescribing schedule. Published obesity trials used once-weekly subcutaneous dosing. TRIUMPH-4 escalated from 2 mg at four-week intervals through 4 mg and 6 mg to 9 mg, and then 12 mg for that target group. Trial participants should follow their study team’s instructions; the three-times-weekly podcast regimen is not validated by these trials.
Does semaglutide cause equal fat and muscle loss?
Does retatrutide burn visceral fat better than other weight loss drugs?
No direct trial establishes that comparison. In its MRI liver substudy, retatrutide 12 mg reduced liver fat by 86.0% relative to baseline at 48 weeks. Liver fat is a different measure from visceral adipose tissue, and the study cannot isolate glucagon’s contribution.
Sources
-
Peptide of the Week. Current creator profile.
-
Nature Medicine. MRI liver-fat substudy.
-
Lancet Diabetes & Endocrinology. Retatrutide body composition in type 2 diabetes.
-
Diabetes, Obesity and Metabolism. SURMOUNT-1 DXA substudy.
-
Denham, JD & Hos, W. (2025). "Peptide of the Week: Retatrutide (GLP-3) – Fat Loss, Brain Boost & Total Control." Peptide of the Week Podcast. Watch on YouTube
-
Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
-
Eli Lilly and Company. (2025). Lilly's triple agonist retatrutide delivered weight loss of up to an average 28.7% in adults with obesity at 68 weeks. Press release
-
Bikou, A., et al. (2024). Changes in body composition under semaglutide treatment in adults: A systematic review. Expert Opinion on Pharmacotherapy.
-
Samms, R.J., et al. (2025). GIP receptor agonism attenuates GLP-1 receptor agonist–induced nausea and emesis. Science Advances. DOI: 10.1126/sciadv.adu1589
-
Li, X., et al. (2024). Structural basis of retatrutide action at GLP-1, GIP, and glucagon receptors. Nature Cell Discovery. DOI: 10.1038/s41421-024-00700-0
- What this is
- Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
- Regulatory status
- Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
- Our standard
- Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
- No commercial ties
- We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.
Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.
Sources
- Peptide of the Week: Retatrutide (YouTube)
YouTube
- Phase 2 trial (NEJM)
New England Journal of Medicine
- GIP attenuates GLP-1 nausea
Science Advances
NEJM
The Lancet
JAMA
FDA
ClinicalTrials.govRelated reading
What Is Retatrutide (GLP-3)?
Eli Lilly’s investigational triple receptor agonist: how it works, what trials show, and why GLP-3 is an informal nickname.
Retatrutide Dosage & Dosing Guide: Titration, Missed Doses, Taper
Phase 3 titration schedule (2→4→6→9→12 mg), missed-dose protocol, taper guidance, and dose-by-dose weight loss data.
Retatrutide Side Effects & Safety Data (2026)
Separate trial tables for retatrutide GI effects and dysesthesia, with rare-event findings and current safety uncertainties.
Does Retatrutide Cause Muscle Loss?
The DXA substudy measured fat and lean-mass reductions. It does not prove a muscle-sparing effect or establish outcomes for every patient.
Retatrutide Results and Review: The Weight Loss Data by Dose
Dose-by-dose trial results, with timepoints, analysis differences and limits on predicting individual weight loss.
Keep exploring
Explore all fact checks topics →